Arbutus Biopharma (ABUS) Equity Income (2018 - 2020)

Arbutus Biopharma has disclosed Equity Income across 3 years of filings, most recently posting $2.5 million for Q4 2020.

• Equity Income for Q4 2020 came in at $2.5 million, up 122.68% year-over-year; the trailing twelve-month figure through Dec 2021 was -$45000.0 (changed 0.0% YoY), and the FY2020 annual result was -$2.5 million, up 88.7% from the prior year.
• Equity Income came in at $2.5 million for Q4 2020 at Arbutus Biopharma, up from -$2.5 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $24.9 million in Q2 2018 to a low of -$11.0 million in Q4 2019.
• The 3-year median for Equity Income is -$2.8 million (2018), against an average of -$358777.8.
• Across the five-year window, Equity Income slumped 304.74% in 2019 and jumped 122.68% in 2020, its largest moves.
• Arbutus Biopharma's Equity Income stood at -$2.7 million in 2018, then sank by 304.74% to -$11.0 million in 2019, then surged by 122.68% to $2.5 million in 2020.
• The last three Equity Income figures came in at $2.5 million (Q4 2020), -$2.5 million (Q3 2020), and -$11.0 million (Q4 2019), per Business Quant data.